Breaking Finance News

VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY) has been downgraded to Hold in a report by Zacks Investment Research today.

Just yesterday VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY) traded 0.00% even at $2.44. VIRALYTICS LTD SPON ADR EACH REPR 3 SHS’s 50-day moving average is $1.49 and its 200-day moving average is $1.44. The last stock price is up 103.34% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.02% over the same time period. 0 shares of VRACY traded hands, down from an average trading volume of 140

Zacks Investment Research has downgraded VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY) to Hold in a report released on 5/25/2017.

Previously on 4/06/2017, Zacks Investment Research released a statement about VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY) increased the target price from $0.00 to $3.25. At the time, this indicated a possible upside of 0.11%.

Recent Performance Chart

VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY)

VIRALYTICS LTD SPON ADR EACH REPR 3 SHS has 52 week low of $1.74 and a 52 week high of $3.50 and has a market capitalization of $0.

Brief Synopsis On VIRALYTICS LTD SPON ADR EACH REPR 3 SHS (NASDAQ:VRACY)

Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The companyÂ’s lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *